Premium
Combined arsenic trioxide and all‐ trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide
Author(s) -
Au W. Y.,
Chim C. S.,
Lie A. K. W.,
Liang R.,
Kwong Y. L.
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2002.03409.x
Subject(s) - arsenic trioxide , acute promyelocytic leukemia , complete remission , retinoic acid , medicine , tretinoin , arsenic , gastroenterology , chemotherapy , chemistry , biochemistry , organic chemistry , gene
Summary. The optimal treatment of acute promyelocytic leukaemia (APL) recurring from relapses successfully treated using arsenic trioxide (As 2 O 3 ) is undefined. Three APL patients relapsing from As 2 O 3 ‐induced remission were studied. Re‐treatment with As 2 O 3 failed in one patient in third relapse, and resulted in morphological but not molecular remission in another patient. Combination therapy with As 2 O 3 and all‐ trans retinoic acid (ATRA), however, resulted in morphological and molecular remission in all three cases, with a follow‐up time ranging from 6 to 16 months. Our results suggest a synergistic therapeutic effect between As 2 O 3 and ATRA in APL in advanced relapse.